Acotec Scientific Holdings Ltd. has announced that it has received registration approval from the PRC National Medical Products Administration for its Vertebral Artery Paclitaxel-coated Balloon Dilatation Catheter, AcoArt Verbena®. This device is intended for percutaneous transluminal angioplasty in symptomatic patients with significant stenosis at the origin of the vertebral artery. The approval marks a significant step in advancing treatment for vertebral artery stenosis, promising a new era of "Leave Nothing Behind" in medical procedures. The clinical trials showed that AcoArt Verbena® had a restenosis rate of 13.04% at 12 months post-procedure, significantly lower than the control group's rate of 37.31%. This approval is a key development for Acotec Scientific Holdings Ltd. as it plans to commence marketing efforts in the PRC market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。